- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05765396
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (PassiveDetect)
The goal of this observational study is to evaluate new non-invasive passive surveillance technologies, Level 42 AI imPulse™ for the detection of COVID-19 in asymptomatic and symptomatic individuals over age of 18 undergoing COVID-19 screening and testing at BAMC Ft Sam Houston, TX; with and without COVID-19.
The hypotheses are:
(H1) The imPulse™ Una e-stethoscope has at least a similar discriminative and detection ability among symptomatic and asymptomatic COVID-19 carrier versus those not infected compared to gold standard RT-PCR. Based on these promising studies, we will operationalize and deploy the imPulseTM Una e-stethoscope and other associated technology form factors into DoD use-cases.
(H2) In the mid to long-term, this approach will also be explored as a diagnostic system to explore pursue the physical (structural and mechanical) properties of cells and tissues that maintain normal cell behavior (motility, growth, apoptosis), and the critical importance of the ability of cells to sense and respond to mechanical stresses, which will be operationally critical for assessment of both traumatic and unconventional exposures in austere environments.
Participants will:
- Be consented;
- Be screened for COVID-19 symptoms according to BAMC's current screening procedures;
- Have study data collected;
- Complete a COVID-19 symptoms questionnaire;
- imPulseTM Una e-stethoscope examination will be conducted;
- Participants will be compensated for completing all study requirements. (Active-Duty personnel must complete the study procedures while off-duty in order to receive compensation.)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Emerging acute respiratory diseases (ARDs) pose a significant threat for the US military, especially among those in training environments where crowded living conditions and demanding multi-factorial stresses exacerbate infection exposure and suppress immunity, respectively. Consequently, ARD rates are routinely reported higher in recruits than older military personnel,which have a detrimental effect on operational readiness. Although significant steps, such as surveillance and vaccine programs, have been taken to minimize the impact that ARDs have on military recruits and newly mobilized troops, hospitalizations among recruits still exceeds that of comparable civilian population in the United States by at least 3- to 4-folds, accounting for almost 30% of all infectious disease associated hospitalizations.
Thus, inexpensive, rapid, and more reliable diagnostics are continually required to better treat and prevent ARDs to preserve military readiness and decrease disability adjusted life years. Current gold standard laboratory procedures for respiratory infection detection are costly, time-consuming, and operator sensitive. It has become apparent that due to the invasive nature of active clinical sampling, there is a critical need for accurate and rapid passive surveillance as to screen for SARS-CoV-19 as well as other hazardous chemical and biological agents. To address this capability gap, the current project aims to deploy novel innovative passive surveillance systems into existing COVID-19 testing lines to validate previous results and validate operational utilization.
The DoD needs fast, accurate, non-invasive, readily scalable, mass screening actionable tests that drive decisions leading to better human, structure, and equipment health outcomes. The required diagnostic tests should first, provide accurate diagnostic information, and second- the diagnostic information, when used in decision-making, should improve human, structure, and equipment health outcomes in a clinically quantifiable way.
The Level 42 AI imPulse™ over-clothing e-stethoscope and stand-off systems are intended to be used to identify characteristic and subtle changes in audible and inaudible sounds changes in the upper and lower respiratory tract driven by airflow velocity, hydration, pressure, and wall shear stress for both inspiration (velocity splitting) and expiration (velocity merging) during active infection vs. health.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Tony T Yuan, PhD
- Phone Number: 214-292-0508
- Email: tony.yuan@usuhs.edu
Study Contact Backup
- Name: Katherine Walker-Rodriguez, MSN
- Phone Number: 210-378-3057
- Email: katherine.c.walker-rodriguez.ctr@health.mil
Study Locations
-
-
Texas
-
Fort Sam Houston, Texas, United States, 78234
- Recruiting
- Brooke Army Medical Center
-
Contact:
- Katherine Walker-Rodriguez, MSN
- Phone Number: 210-378-3057
- Email: katherine.c.walker-rodriguez.ctr@health.mil
-
Contact:
- Tony Yuan, PhD
- Email: tony.yuan@usuhs.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Asymptomatic and symptomatic individuals 18 years and older
- Receiving standard COVID-19 screening and testing at BAMC
- Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened
- English Speaking
Exclusion Criteria:
- Any individual under age of 18
- Anyone unable to comply (or be assisted) with study procedures
- Anyone not able to provide temperature thermal scan, and/or 3-minute vibroacoustic scan
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
COVID-19 positive patients
Participants screened with known COVID-19 positive test results obtained within 48hrs of recruitment.
|
The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
Other Names:
|
COVID-19 negative patients
Participants screened with known COVID-19 negative test results obtained within 48hrs of recruitment.
|
The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Digital vibroacoustic biomarker diagnostic performance characteristics
Time Frame: Enrollment through to study completion (min 48hrs through to 12 months)
|
Sensitivity, specificity, positive and negative predictive values - of the imPulse™ Una device for point-of-care diagnosis of COVID-19 among symptomatic and asymptomatic COVID-19 carrier versus those not infected compared to gold standard RT-PCR.
|
Enrollment through to study completion (min 48hrs through to 12 months)
|
imPulse™ Una infrasound-to-ultrasound e-stethoscope device usability
Time Frame: Enrollment through to study completion (min 48hrs through to 12 months)
|
Critical importance of the ability to sense and respond to mechanical stresses, which will be operationally critical for assessment of both traumatic and unconventional exposures in austere environments
|
Enrollment through to study completion (min 48hrs through to 12 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tony T Yuan, PhD, Uniformed Services University of the Health Sciences (USUHS)
- Principal Investigator: Michael Morris, MD, Brooke Army Medical Center
Publications and helpful links
General Publications
- Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013 Aug 1;369(5):448-57. doi: 10.1056/NEJMra1201534. No abstract available.
- Sanchez JL, Cooper MJ, Myers CA, Cummings JF, Vest KG, Russell KL, Sanchez JL, Hiser MJ, Gaydos CA. Respiratory Infections in the U.S. Military: Recent Experience and Control. Clin Microbiol Rev. 2015 Jul;28(3):743-800. doi: 10.1128/CMR.00039-14.
- Clemmons NS, McCormic ZD, Gaydos JC, Hawksworth AW, Jordan NN. Acute Respiratory Disease in US Army Trainees 3 Years after Reintroduction of Adenovirus Vaccine 1. Emerg Infect Dis. 2017 Jan;23(1):95-98. doi: 10.3201/eid2301.161297. Epub 2017 Jan 15.
- Armed Forces Health Surveillance Center (AFHSC). Surveillance Snapshot: illness and injury burdens among U.S. military recruit trainees, 2012. MSMR. 2013 Apr;20(4):24. No abstract available.
- Alahi MEE, Mukhopadhyay SC. Detection Methodologies for Pathogen and Toxins: A Review. Sensors (Basel). 2017 Aug 16;17(8):1885. doi: 10.3390/s17081885.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Coronavirus Infections
- Infections
- Communicable Diseases
- Respiratory Tract Infections
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
Other Study ID Numbers
- C.2023.007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on imPulse™ Una infrasound-to-ultrasound e-stethoscope
-
Level 42 AI, Inc.Asian Institute of Public Health; Institut de Recherche en Santé de Surveillance... and other collaboratorsCompletedCovid19 | Corona Virus Infection | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | Mass Screening | Vaccine Virus SheddingCongo, The Democratic Republic of the, India, Senegal
-
Level 42 AI, Inc.Georgetown UniversityRecruitingPremature Birth | Prematurity | Premature Lungs | Prematurity; ExtremeUnited States
-
Level 42 AI, Inc.Johns Hopkins University; Schmidt FuturesCompletedCorona Virus Infection | CoronavirusUnited States